http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 26 Jun 2026 16:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+26/26698729.html si-local-file:///var/storage/secattach/20260626/26698729.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+26/26698729.html Fri, 26 Jun 2026 16:07:00 -0400 O.01584314 SNGX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+26/26698729.html si-local-file:///var/storage/secattach/20260626/26698729.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+26/26698729.html Fri, 26 Jun 2026 16:07:00 -0400 O.01584314 SNGX http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26698686.html si-local-file:///var/storage/secattach/20260626/26698686.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26698686.html Fri, 26 Jun 2026 16:05:00 -0400 O.01584314 SNGX http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26698686.html si-local-file:///var/storage/secattach/20260626/26698686.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26698686.html Fri, 26 Jun 2026 16:05:00 -0400 O.01584314 SNGX http://www.streetinsider.com/Press+Releases/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html <p><span id="ctl00_main_lblInstructions">Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - </span>Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak.</p><p style="text-align: center;"><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg"><img src="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" style="border-width: 0px;" alt="Cannot view this image? Visit: https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" /></a><br /><br />From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak</p><p style="text-align: center;">To view an enhanced version of this graphic, please visit:<br /><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg">https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg</a></p><p>According to a recent <a href="https://api.newsfilecorp.com/redirect/mjkJLs44mv">ABC news headline</a> - "France confirms 1st Ebola case linked to DRC as UN http://www.streetinsider.com/Press+Releases/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html Fri, 26 Jun 2026 07:00:00 -0400 AEMD MRNA REGN SNGX http://www.streetinsider.com/Press+Releases/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html <p><span id="ctl00_main_lblInstructions">Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - </span>Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak.</p><p style="text-align: center;"><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg"><img src="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" style="border-width: 0px;" alt="Cannot view this image? Visit: https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" /></a><br /><br />From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak</p><p style="text-align: center;">To view an enhanced version of this graphic, please visit:<br /><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg">https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg</a></p><p>According to a recent <a href="https://api.newsfilecorp.com/redirect/mjkJLs44mv">ABC news headline</a> - "France confirms 1st Ebola case linked to DRC as UN http://www.streetinsider.com/Press+Releases/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html Fri, 26 Jun 2026 07:00:00 -0400 AEMD MRNA REGN SNGX http://www.streetinsider.com/Press+Releases/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html <p><span id="ctl00_main_lblInstructions">Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - </span>Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak.</p><p style="text-align: center;"><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg"><img src="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" style="border-width: 0px;" alt="Cannot view this image? Visit: https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" /></a><br /><br />From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak</p><p style="text-align: center;">To view an enhanced version of this graphic, please visit:<br /><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg">https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg</a></p><p>According to a recent <a href="https://api.newsfilecorp.com/redirect/mjkJLs44mv">ABC news headline</a> - "France confirms 1st Ebola case linked to DRC as UN http://www.streetinsider.com/Press+Releases/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html Fri, 26 Jun 2026 07:00:00 -0400 AEMD MRNA REGN SNGX http://www.streetinsider.com/Press+Releases/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html <p><span id="ctl00_main_lblInstructions">Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - </span>Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak.</p><p style="text-align: center;"><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg"><img src="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" style="border-width: 0px;" alt="Cannot view this image? Visit: https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" /></a><br /><br />From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak</p><p style="text-align: center;">To view an enhanced version of this graphic, please visit:<br /><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg">https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg</a></p><p>According to a recent <a href="https://api.newsfilecorp.com/redirect/mjkJLs44mv">ABC news headline</a> - "France confirms 1st Ebola case linked to DRC as UN http://www.streetinsider.com/Press+Releases/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html Fri, 26 Jun 2026 07:00:00 -0400 AEMD MRNA REGN SNGX http://www.streetinsider.com/Newsfile/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html <p><span id="ctl00_main_lblInstructions">Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - </span>Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak.</p><p style="text-align: center;"><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg"><img src="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" style="border-width: 0px;" alt="Cannot view this image? Visit: https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" /></a><br /><br />From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak</p><p style="text-align: center;">To view an enhanced version of this graphic, please visit:<br /><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg">https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg</a></p><p>According to a recent <a href="https://api.newsfilecorp.com/redirect/mjkJLs44mv">ABC news headline</a> - "France confirms 1st Ebola case linked to DRC as UN http://www.streetinsider.com/Newsfile/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html Fri, 26 Jun 2026 07:00:00 -0400 AEMD MRNA REGN SNGX http://www.streetinsider.com/Newsfile/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html <p><span id="ctl00_main_lblInstructions">Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - </span>Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak.</p><p style="text-align: center;"><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg"><img src="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" style="border-width: 0px;" alt="Cannot view this image? Visit: https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" /></a><br /><br />From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak</p><p style="text-align: center;">To view an enhanced version of this graphic, please visit:<br /><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg">https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg</a></p><p>According to a recent <a href="https://api.newsfilecorp.com/redirect/mjkJLs44mv">ABC news headline</a> - "France confirms 1st Ebola case linked to DRC as UN http://www.streetinsider.com/Newsfile/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html Fri, 26 Jun 2026 07:00:00 -0400 AEMD MRNA REGN SNGX http://www.streetinsider.com/Newsfile/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html <p><span id="ctl00_main_lblInstructions">Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - </span>Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak.</p><p style="text-align: center;"><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg"><img src="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" style="border-width: 0px;" alt="Cannot view this image? Visit: https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" /></a><br /><br />From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak</p><p style="text-align: center;">To view an enhanced version of this graphic, please visit:<br /><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg">https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg</a></p><p>According to a recent <a href="https://api.newsfilecorp.com/redirect/mjkJLs44mv">ABC news headline</a> - "France confirms 1st Ebola case linked to DRC as UN http://www.streetinsider.com/Newsfile/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html Fri, 26 Jun 2026 07:00:00 -0400 AEMD MRNA REGN SNGX http://www.streetinsider.com/Newsfile/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html <p><span id="ctl00_main_lblInstructions">Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - </span>Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak.</p><p style="text-align: center;"><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg"><img src="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" style="border-width: 0px;" alt="Cannot view this image? Visit: https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001.jpg" /></a><br /><br />From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak</p><p style="text-align: center;">To view an enhanced version of this graphic, please visit:<br /><a rel="nofollow" href="https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg">https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpg</a></p><p>According to a recent <a href="https://api.newsfilecorp.com/redirect/mjkJLs44mv">ABC news headline</a> - "France confirms 1st Ebola case linked to DRC as UN http://www.streetinsider.com/Newsfile/From+Vaccines+to+Therapeutics%3B+How+Biotech+Is+Addressing+the+Ebola+Outbreak/26694891.html Fri, 26 Jun 2026 07:00:00 -0400 AEMD MRNA REGN SNGX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++SOLIGENIX%2C+INC.++++++++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/26691872.html si-local-file:///var/storage/secattach/20260625/26691872.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++SOLIGENIX%2C+INC.++++++++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/26691872.html Thu, 25 Jun 2026 15:27:00 -0400 O.01584314 SNGX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++SOLIGENIX%2C+INC.++++++++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/26691872.html si-local-file:///var/storage/secattach/20260625/26691872.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++SOLIGENIX%2C+INC.++++++++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/26691872.html Thu, 25 Jun 2026 15:27:00 -0400 O.01584314 SNGX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+10/26640725.html si-local-file:///var/storage/secattach/20260612/26640725.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+10/26640725.html Fri, 12 Jun 2026 16:07:00 -0400 O.01584314 SNGX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+10/26640725.html si-local-file:///var/storage/secattach/20260612/26640725.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+10/26640725.html Fri, 12 Jun 2026 16:07:00 -0400 O.01584314 SNGX http://www.streetinsider.com/Corporate+News/Soligenix+applies+for+CEPI+funding+to+develop+Bundibugyo+Ebola+vaccine/26614324.html <p>Soligenix Inc. (NASDAQ: SNGX) announced it will apply for funding from the Coalition for Epidemic Preparedness Innovations to develop a vaccine for Bundibugyo virus, with applications due June 12, 2026.</p><p>The Princeton, New Jersey-based biopharmaceutical company will collaborate with Dr. Axel Lehrer from the University of Hawaii at Manoa on the application. The team previously developed bivalent and trivalent thermostable vaccines against Ebola virus, Sudan virus and Marburg virus using the CoVaccine HT adjuvant.</p><p>According to the press release, these vaccines demonstrated thermostability, immunogenicity and efficacy in non-human primates. The vaccines showed up to 100% protection in non-human primates and maintained stability http://www.streetinsider.com/Corporate+News/Soligenix+applies+for+CEPI+funding+to+develop+Bundibugyo+Ebola+vaccine/26614324.html Mon, 08 Jun 2026 07:31:15 -0400 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4705749-1&amp;h=4154964116&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4705749-1&amp;h=4154964116&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4705749-1&amp;h=4154964116&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4705749-1&amp;h=4154964116&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4705749-1&amp;h=4154964116&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4705749-1&amp;h=4154964116&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4705749-1&amp;h=4154964116&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4705749-1&amp;h=4154964116&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX